MMP9 and melanoma: Indeed, the PFS and OS analyses according to the circulating-free DNA BRAFV600E status and the MMP-9 expression levels showed a worse prognosis for melanoma patients with detectable circulating BRAFV600E mutation and high MMP-9 serum levels (>680 ng/mL) compared with those with undetectable mutation and lower levels of MMP-9.